These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. Hall AP; Westwood FR; Wadsworth PF Toxicol Pathol; 2006; 34(2):131-47. PubMed ID: 16537292 [TBL] [Abstract][Full Text] [Related]
16. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496 [TBL] [Abstract][Full Text] [Related]
17. Targeted in vivo imaging of angiogenesis: present status and perspectives. Choe YS; Lee KH Curr Pharm Des; 2007; 13(1):17-31. PubMed ID: 17266586 [TBL] [Abstract][Full Text] [Related]
19. Antiangiogenesis, anti-VEGF(R) and outlook. Petersen I Recent Results Cancer Res; 2007; 176():189-99. PubMed ID: 17607926 [TBL] [Abstract][Full Text] [Related]
20. Spatial distribution of VEGF isoforms and chemotactic signals in the vicinity of a tumor. Small AR; Neagu A; Amyot F; Sackett D; Chernomordik V; Gandjbakhche A J Theor Biol; 2008 Jun; 252(4):593-607. PubMed ID: 18395755 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]